Optimal treatment of Alzheimer’s disease psychosis: challenges and solutions
Jeremy Koppel,1,2 Blaine S Greenwald2 1The Feinstein Institute for Medical Research, North Shore–Long Island Jewish Health System, Manhasset, NY, USA; 2Zucker Hillside Hospital, Hofstra North Shore-Long Island Jewish School of Medicine, Glen Oaks, NY, USA Abstract: Psychotic symptoms em...
Guardado en:
Autores principales: | Koppel J, Greenwald BS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3d479cac9fa34f3b840d95db69aebe64 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs BL, et al.
Publicado: (2017) -
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
por: Paul Shotbolt, et al.
Publicado: (2009) -
Neuroinflammation in Alzheimer’s disease
por: Zhang FJ, et al.
Publicado: (2015) -
The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence
por: Tousi B
Publicado: (2015) -
Optimal management of Alzheimer’s disease patients: Clinical guidelines and family advice
por: Julia Haberstroh, et al.
Publicado: (2010)